Keros Therapeutics, Inc. (KROS) cash on hand

Cash · fiscal 2025
$287.42M

Keros Therapeutics, Inc. (KROS) held cash of $287.42M at the end of fiscal 2025 (December 31, 2025). That is 48.7% lower than the $559.93M of fiscal 2024. Figures as of 18 Nov 2026, 12:10 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$287.42M
Change on fiscal 2024
−48.7%
Highest on record
$559.93Mfiscal 2024
Lowest on record
$279.05Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Keros Therapeutics, Inc. cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $559.93M in fiscal 2024 and the lowest $279.05M in fiscal 2022.

History · 4 fiscal years

Cash by fiscal year

Keros Therapeutics, Inc. cash on hand, year by year

Keros Therapeutics, Inc. (KROS) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$287.42M 48.7% down
2024$559.93M 69.1% up
2023$331.15M 18.7% up
2022$279.05M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

More on KROS

Keros Therapeutics, Inc., figure by figure

Keros Therapeutics, Inc. (KROS) overview: price, valuation and scorecard

Keros Therapeutics, Inc. cash on hand: questions and answers

How much cash does Keros Therapeutics, Inc. have?

Keros Therapeutics, Inc. (KROS) held cash of $287.42M at the end of fiscal 2025 (December 31, 2025). That is 48.7% lower than the $559.93M of fiscal 2024.

What are the highest and lowest cash figures on record for Keros Therapeutics, Inc.?

Across the 4 fiscal years on record (2022–2025), the highest was $559.93M in fiscal 2024 and the lowest $279.05M in fiscal 2022.

How is Keros Therapeutics, Inc.'s cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Keros Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Keros Therapeutics, Inc. (KROS) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/KROS/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.